ライフサイエンスコーパス: aspirin

1 re included, including 3,237 (34%) receiving aspirin.

2 let and non-platelet eicosanoids affected by aspirin.

3 mg twice daily) plus aspirin or placebo plus aspirin.

4 iratory disease-like (ptges1(-/-)) mice with aspirin.

5 mg aspirin daily or rivaroxaban placebo plus aspirin.

6 min K antagonist (VKA) and with placebo than aspirin.

7 riptions for 90 or more consecutive doses of aspirin.

8 dopt preventive strategies, such as low-dose aspirin.

9 l patients were on clopidogrel 75 mg/day and aspirin.

10 REDS2 participants, 1198 (49.9%) were taking aspirin.

11 asurably lower in cardiology patients taking aspirin.

12 These patients are generally treated with aspirin.

13 75 to 100 mg daily) or matching placebo plus aspirin.

14 most famous being salicin, the progenitor of aspirin.

15 them to anti- and pro-thrombotic effects of aspirin.

16 (2001-2020) that studied discontinuation of aspirin 1 to 3 months after PCI with continued P2Y(12) i

17 were randomized (1:1:1) to receive 100 mg of aspirin 1, 2, or 3 times daily for 2 weeks.

18 eeding was observed for recent initiators of aspirin (1.40; 1.13-1.72;p = 0.002) but not for those co

19 with GFR >=60 ml/min (2.9% rivaroxaban plus aspirin, 1.6% aspirin alone, HR: 1.81; 95% CI: 1.44 to 2

20 daily plus aspirin 100 mg once daily versus aspirin 100 mg once daily reduced the primary major adve

21 PI) with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily versus aspirin 100 mg once dai

22 cts of rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) versus placebo plus aspirin in pa

23 Routine perioperative use of low-dose aspirin (100 mg/d) does not decrease cardiovascular even

24 Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first

25 e with GFR <60 ml/min (3.9% rivaroxaban plus aspirin, 2.7% aspirin alone, HR: 1.47, 95% CI: 1.05 to 2

26 initial concentration 70 mg/L, using 2000 mg aspirin, (2) carbamazepine, initial concentration 35 mg/

27 2016, respectively, from 57.3% to 64.3% for aspirin, 3.6% to 24.8% for clopidogrel, and 36.2% to 77.

28 ing dose followed by 90 mg twice daily) plus aspirin (300 to 325 mg on the first day followed by 75 t

29 s were randomly assigned to receive low-dose aspirin (5990 women) or placebo (5986 women).

30 significantly between users and nonusers of aspirin (7.8% and 6.9%, respectively; difference, 0.9 pe

31 de, and 10 mg of ramipril) or placebo daily, aspirin (75 mg) or placebo daily, and vitamin D or place

32 hrombotic strategy (rivaroxaban [10 mg] plus aspirin [75 to 100 mg] once daily) or an antiplatelet-ba

33 let-based strategy (clopidogrel [75 mg] plus aspirin [75 to 100 mg] once daily).

34 G to ticagrelor or placebo added to standard aspirin (80 mg or 100 mg).

35 masked, placebo-controlled trial of low-dose aspirin (81 mg daily) initiated between 6 weeks and 0 da

36 naproxen (95% CI: 0.85, 1.35), and 1.05 for aspirin (95% CI: 0.81, 1.35), as compared with nonuse of

37 telet activation as an efficacious target of aspirin, a widely available and affordable host-directed

38 ntieth century, coincident with marketing of aspirin-a signature event in the history of modern drug

39 whether the anti-inflammatory activities of aspirin (acetylsalicylic acid [ASA]) could protect again

40 lts explain why increasing aspirin dosage or aspirin addition to other drugs may lessen antithromboti

41 oronary syndrome, in whom discontinuation of aspirin after 1 to 3 months reduced bleeding by 50% (1.7

42 n making on the ideal duration of the use of aspirin after an acute coronary syndrome or percutaneous

43 is commonly used as a short-term adjunct to aspirin after endovascular revascularization.

44 data support the addition of rivaroxaban to aspirin after lower extremity revascularization regardle

45 ge >40 years, coronary artery bypass, and no aspirin after LT as independent risk factors for early o

46 of coronary artery calcium (CAC) for guiding aspirin allocation for primary prevention by using 2019

47 e cardiovascular events (MACE) compared with aspirin alone after percutaneous coronary intervention (

48 tal of 331 patients were assigned to receive aspirin alone and 334 were assigned to receive aspirin p

49 nt occurred in 76 patients (23.0%) receiving aspirin alone and in 104 (31.1%) receiving aspirin plus

50 nt occurred in 50 patients (15.1%) receiving aspirin alone and in 89 (26.6%) receiving aspirin plus c

51 in resistance than all patients treated with aspirin alone and TCT decreased the frequency of aspirin

52 alone as compared with matching placebo, for aspirin alone as compared with matching placebo, and for

53 Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA.

54 with rivaroxaban 2.5 mg plus aspirin versus aspirin alone in those with GFR >=60 ml/min (2.9% rivaro

55 anticoagulation, in a 1:1 ratio, to receive aspirin alone or aspirin plus clopidogrel for 3 months.

56 was lower with ticagrelor-aspirin than with aspirin alone, but the incidence of disability did not d

57 ml/min (3.9% rivaroxaban plus aspirin, 2.7% aspirin alone, HR: 1.47, 95% CI: 1.05 to 2.07).

58 ml/min (2.9% rivaroxaban plus aspirin, 1.6% aspirin alone, HR: 1.81; 95% CI: 1.44 to 2.28) and simil

59 thout a previous PCI treated with DPI versus aspirin alone.

60 ke, or death from cardiovascular causes than aspirin alone.

61 igher with rivaroxaban and aspirin than with aspirin alone.

62 coronary intervention and the withholding of aspirin among patients with both CCS and atrial fibrilla

63 ere reported in 36 participants who received aspirin and 36 participants who received placebo.

64 or placebo; 427 (50%) participants received aspirin and 434 (50%) placebo.

65 ccurred in 668 (11.6%) of the women who took aspirin and 754 (13.1%) of those who took placebo (RR 0.

66 Dual antiplatelet therapy with aspirin and a P2Y(12) inhibitor has been shown to reduce

67 et count that can be partially reversed with aspirin and a P2Y12 antagonist.

68 Concomitant aspirin and anticoagulation in critically ill surgical p

69 matic thrombosis occurred and resolved under aspirin and anticoagulation therapy.

70 In conclusion, patients on aspirin and clopidogrel had a higher incidence of aspiri

71 Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of isch

72 utcome except for reduced co-prescription of aspirin and clopidogrel without gastro-protection in pat

73 Results showed that in patients taking aspirin and clopidogrel, the incidence of aspirin resist

74 report clinical benefit when desensitized to aspirin and maintained on daily aspirin therapy.

75 tion, such that a strong association between aspirin and major bleeding was observed for recent initi

76 disease without safety concerns around using aspirin and meeting trial eligibility criteria.

77 by chronic rhinosinusitis and intolerance of aspirin and other COX1 inhibitors.

78 develop bronchospasm after the ingestion of aspirin and other nonsteroidal anti-inflammatory drugs,

79 us triple therapy (vitamin K antagonist plus aspirin and P2Y12 inhibitor) in patients with nonvalvula

80 events during the intervention phase between aspirin and placebo groups were similar, and no signific

81 s to 6 months with apixaban and VKA and with aspirin and placebo.

82 ll surgical patients may receive concomitant aspirin and therapeutic anticoagulation postoperatively,

83 , all 3 of our patients were taking low-dose aspirin and/or clopidogrel as secondary cardiovascular p

84 redient (ibuprofen, acetaminophen, naproxen, aspirin) and cumulative monthly dose.

85 relor Compared to Placebo on a Background of Aspirin), and FOURIER (Further Cardiovascular Outcomes R

86 AREDS participants, 1049 (28.1%) were taking aspirin, and of the 2403 eligible AREDS2 participants, 1

87 ry syndrome were randomly assigned to DPI or aspirin, and, of these, 9862 (59.6%) had previous PCI (m

88 ose tissue of OSA patients receiving statin, aspirin, and/or RAS inhibitors was comparable to non-OSA

89 cent studies have highlighted the utility of aspirin as a host-directed therapy modulating the inflam

90 matching placebo, and for the polypill plus aspirin as compared with double placebo.

91 ated fatty acids (omega-3 PUFA) and low-dose aspirin (ASA) have been proposed as a host modulation re

92 .5 mg twice daily plus acetylsalicylic acid (aspirin; ASA) 100 mg reduced the risk of cardiovascular

93 r the first 3 months) (rivaroxaban group) or aspirin at a dose of 75 to 100 mg daily (with clopidogre

94 e rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3

95 Intervention with aspirin, atorvastatin or renin-angiotensin system (RAS)

96 afety of a four-component polypill including aspirin, atorvastatin, hydrochlorothiazide, and either e

97 linical benefit of low-dose rivaroxaban plus aspirin, but at the expense of increased bleeding risk i

98 The antiplatelet response to low-dose aspirin can be markedly improved by shortening the dosin

99 From randomization to 30 days, aspirin caused more severe bleeding (absolute risk diffe

100 and aspirin-tolerant (n = 82) who underwent aspirin challenge from May 2014 to May 2018.

101 203769 attenuated AHR induced by allergen or aspirin challenge of wild-type or ptges1(-/-) mice, resp

102 Although it cannot replace the gold-standard aspirin challenge test, the implementation of the ANN mi

103 up Report provides a comprehensive review of aspirin challenges, aspirin desensitizations, and mainte

104 tality through colonoscopic surveillance and aspirin chemoprevention; it also enables cascade testing

105 We examined temporal changes in the use of aspirin, clopidogrel, and statins and 1-year cause-speci

106 ) inhibitor), dual antiplatelet therapy (eg, aspirin combined with a P2Y(12) inhibitor), and dual-pat

107 rs (n=14 005) who were discharged alive with aspirin combined with either clopidogrel (60.2%) or tica

108 inhibitor), and dual-pathway inhibition (eg, aspirin combined with the vascular dose of the direct or

109 The primary outcome for the aspirin comparison occurred in 116 participants (4.1%) i

110 The primary outcome for the polypill-plus-aspirin comparison occurred in 59 participants (4.1%) in

111 For the aspirin comparison, the primary outcome was death from c

112 For the polypill-alone and polypill-plus-aspirin comparisons, the primary outcome was death from

113 rios, including early discontinuation of the aspirin component of dual antiplatelet therapy after per

114 ly 5% of MESA participants would qualify for aspirin consideration for primary prevention according t

115 After 30 days, aspirin continues to increase bleeding without significa

116 ome were randomly assigned to receive 600 mg aspirin daily or placebo.

117 o rivaroxaban 2.5 mg twice daily plus 100 mg aspirin daily or rivaroxaban placebo plus aspirin.

118 comprehensive review of aspirin challenges, aspirin desensitizations, and maintenance aspirin therap

119 40 (9%) of 427 participants who received aspirin developed colorectal cancer compared with 58 (13

120 Mice on aspirin developed lower fibrosis and extent compared wit

121 ntibody (82.3 vs. 69.2 AU; P < 0.07) but not aspirin dialuminate (82.1 vs. 79.5 AU; P > 0.05).

122 rial, the addition of ticagrelor to standard aspirin did not reduce SVG occlusion at 1 year after CAB

123 ong aspirin users and 8.3% among nonusers of aspirin (difference, -4.3 percentage points; 95% confide

124 The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhib

125 stroke (i.e., rates were not increased with aspirin discontinuation prior to anticoagulation).

126 These results explain why increasing aspirin dosage or aspirin addition to other drugs may le

127 tion of a computable phenotype in ADAPTABLE (Aspirin Dosing: a Patient-Centric Trial Assessing Benefi

128 Here, we have shown that aspirin dramatically reduced lung metastasis through inh

129 Aspirin-exacerbated respiratory disease (AERD) is a mech

130 Aspirin-exacerbated respiratory disease (AERD) is charac

131 Aspirin-exacerbated respiratory disease (AERD) is charac

132 The cause of severe nasal polyposis in aspirin-exacerbated respiratory disease (AERD) is unknow

133 enhanced LTC(4) synthesis similar to that in aspirin-exacerbated respiratory disease, completely bloc

134 ssociated bronchoconstriction by challenging aspirin-exacerbated respiratory disease-like (ptges1(-/-

135 properties of desensitization to aspirin in aspirin-exacerbated respiratory disease.

136 l anti-inflammatory drugs, a disorder termed aspirin-exacerbated respiratory disease.

137 ), a similar trial treating with clopidogrel-aspirin for 21 days and showing no increase in major hem

138 n in acute stroke; early or first aid use of aspirin for chest pain; control of life-threatening blee

139 Aspirin for primary atherosclerotic cardiovascular disea

140 vascular disease, the efficacy and safety of aspirin for primary prevention has become uncertain.

141 Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with establ

142 l clinical trial testing the optimal dose of aspirin for secondary prevention of atherosclerotic card

143 tor targets, indicating that the efficacy of aspirin for secondary prevention of CCS may similarly ha

144 raise some uncertainty as to the primacy of aspirin for the lifelong management of all patients with

145 Whether the benefits of aspirin for the primary prevention of cardiovascular dis

146 irin group and in 345 patients (6.3%) in the aspirin group (hazard ratio, 0.79; 95% CI, 0.68 to 0.93;

147 irin group and in 362 patients (6.6%) in the aspirin group (hazard ratio, 0.83; 95% confidence interv

148 d significantly reduced overall risk for the aspirin group (HR=0.63, 0.43-0.92; p=0.018).

149 spirin group and in 7 patients (0.1%) in the aspirin group (P = 0.001).

150 erwent randomization (5523 in the ticagrelor-aspirin group and 5493 in the aspirin group).

151 5780 women in the aspirin group and 5764 in the placebo group were evaluab

152 n occurred in 116 participants (4.1%) in the aspirin group and in 134 (4.7%) in the placebo group (ha

153 red in 276 patients (5.0%) in the ticagrelor-aspirin group and in 345 patients (6.3%) in the aspirin

154 red in 303 patients (5.5%) in the ticagrelor-aspirin group and in 362 patients (6.6%) in the aspirin

155 rred in 28 patients (0.5%) in the ticagrelor-aspirin group and in 7 patients (0.1%) in the aspirin gr

156 om 861 agreed to be randomly assigned to the aspirin group or placebo; 427 (50%) participants receive

157 the ticagrelor-aspirin group and 5493 in the aspirin group).

158 multiple blood-pressure-lowering drugs, and aspirin has been proposed to reduce the risk of cardiova

159 A total of 95 asthma patients with aspirin hypersensitivity underwent sputum induction.

160 sults support a more complex pathobiology of aspirin hypersensitivity.

161 Use of aspirin immediately and for up to 30 days results in an

162 tigated whether ticagrelor added to standard aspirin improves SVG patency at 1 year after CABG.

163 therapeutic properties of desensitization to aspirin in aspirin-exacerbated respiratory disease.

164 llenging the previously unquestioned role of aspirin in CCS have come from recent trials where aspiri

165 The safety of discontinuing aspirin in favor of P2Y(12) inhibitor monotherapy remain

166 The Effects of Aspirin in Gestation and Reproduction Trial (2006-2012)

167 ase for prevention of colorectal cancer with aspirin in Lynch syndrome is supported by our results.

168 to consistently demonstrate net benefit for aspirin in patients treated to optimal contemporary card

169 s aspirin (100 mg daily) versus placebo plus aspirin in patients with diabetes mellitus versus withou

170 evious trial, ticagrelor was not better than aspirin in preventing vascular events or death after str

171 in a more personalized, safer allocation of aspirin in primary prevention.

172 cohort equations to inform the allocation of aspirin in primary prevention.

173 thy older adults using data from the ASPREE (Aspirin in Reducing Events in the Elderly) trial.

174 her study of the universal need for lifelong aspirin in secondary prevention for all adults with CCS,

175 rials: the NAVIGATE ESUS (Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention

176 aboration, solidified the historical role of aspirin in secondary prevention.

177 Although the benefit of aspirin in the immediate phase after a myocardial infarc

178 e the first trial suggesting the efficacy of aspirin in the secondary prevention of myocardial infarc

179 m assessment of the effect of taking regular aspirin in this high-risk population.

180 CE was not observed after discontinuation of aspirin, including in patients with acute coronary syndr

181 ng airway PGE2 biosynthesis in allergen- and aspirin-induced asthma.

182 e older patients who are at highest risk for aspirin-induced bleeding.

183 of prostaglandin E(2) (PGE(2)) contribute to aspirin-induced hypersensitivity.

184 prostaglandin D(2) metabolite levels during aspirin-induced reactions in the study population as a w

185 o therapeutic concentration in 460 min while aspirin infusion reduces that time to 330 min.

186 he physiologic response to subsequent lysine-aspirin inhalation challenges, as well as increases in l

187 income and middle-income countries, low-dose aspirin initiated between 6 weeks and 0 days of gestatio

188 out established CAD, primary prevention with aspirin is not routinely advocated because of its increa

189 Low-dose aspirin is recommended for prophylaxis in high-risk popu

190 estigated the possibility that the effect of aspirin is related to an antiplatelet mode of action.

191 Once-daily low-dose aspirin is the recommended antithrombotic regimen, but a

192 outweigh the risks of bleeding, and low-dose aspirin is uniformly recommended in this setting.

193 Combined treatment with a polypill plus aspirin led to a lower incidence of cardiovascular event

194 However, the non-platelet actions of aspirin limit its antithrombotic effects.

195 use of preventive pharmacotherapies, such as aspirin, lipid-lowering mediations, and cardiometabolic

196 eded about the long-term effects of low-dose aspirin (<=160 mg) on incident hepatocellular carcinoma,

197 ocation for primary prevention by using 2019 aspirin meta-analysis data on cardiovascular disease rel

198 0.45-0.83]), and short-term DAPT followed by aspirin monotherapy (absolute risk difference, -6.1 inci

199 on to conventional 12-month DAPT followed by aspirin monotherapy in the reduction of the primary comp

200 with midterm or short-term DAPT followed by aspirin monotherapy, with the exception that short-term

201 olled trials including 165,502 participants (aspirin n = 83,529, control n = 81,973) were available f

202 Patients on chronic once-daily low-dose aspirin (n = 245) were randomized (1:1:1) to receive 100

203 an plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in patients both with (n=6922) and with

204 ion was seen for benefit of rivaroxaban plus aspirin (n=9152) versus placebo plus aspirin (n=9126) in

205 Benefit/harm calculations were restricted to aspirin-naive participants <70 years of age not at high

206 ention agents that have been studied include aspirin, nonaspirin nonsteroidal anti-inflammatory drugs

207 s related to the following variables: use of aspirin/NSAIDs/anti-coagulants/anti-platelets, pathologi

208 of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in p

209 effect of the combination of ticagrelor and aspirin on prevention of stroke has not been well studie

210 therapy regimen rates were determined (none, aspirin only, P2Y12 inhibitor only, and DAPT).

211 nclude single antiplatelet therapy (eg, with aspirin or a P2Y(12) inhibitor), dual antiplatelet thera

212 ubstudy within the TWILIGHT (Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary In

213 Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA

214 tening bleeding compared with treatment with aspirin or clopidogrel alone in patients at high risk fo

215 The combination of cilostazol with aspirin or clopidogrel had a reduced incidence of ischae

216 Conversely, aspirin or lack of systemic COX-1 activity decreased the

217 pared short-term (<6-month) DAPT followed by aspirin or P2Y12 inhibitor monotherapy; midterm (6-month

218 P2Y(12) inhibitor were randomized to blinded aspirin or placebo and to open-label apixaban or VKA for

219 eceive rivaroxaban (2.5 mg twice daily) plus aspirin or placebo plus aspirin.

220 men with previous pregnancy loss to low dose aspirin or placebo prior to conception.

221 ssigned (1:1, stratified by site) to receive aspirin or placebo tablets of identical appearance, via

222 deline-directed medical therapies, including aspirin (p < 0.001), statin (p < 0.001), and beta-blocke

223 icoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocia

224 xaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibrillation and

225 g aspirin alone and in 104 (31.1%) receiving aspirin plus clopidogrel (difference, -8.2 percentage po

226 ng aspirin alone and in 89 (26.6%) receiving aspirin plus clopidogrel (risk ratio, 0.57; 95% confiden

227 icantly less frequent with aspirin than with aspirin plus clopidogrel administered for 3 months.

228 in a 1:1 ratio, to receive aspirin alone or aspirin plus clopidogrel for 3 months.

229 pirin alone and 334 were assigned to receive aspirin plus clopidogrel.

230 n stable atherosclerosis, the combination of aspirin plus rivaroxaban 2.5 mg twice daily provided a s

231 e patients would benefit from treatment with aspirin plus ticagrelor.

232 Aspirin-precipitated bronchoconstriction is associated w

233 nsteroidal anti-inflammatory drug use except aspirin prescribed for secondary prevention of cardiovas

234 Aspirin prevents thrombosis by inhibiting platelet cyclo

235 n those with previous PCI, DPI compared with aspirin produced consistent (robust) reductions in MACE

236 Regardless of previous PCI, DPI versus aspirin produced consistent reductions in MACE (PCI: 4.0

237 DPI compared with aspirin produced consistent reductions in MACE and morta

238 In the VOYAGER PAD trial, rivaroxaban plus aspirin reduced the risk of adverse cardiovascular and l

239 In conclusion, the currently recommended aspirin regimen of 75 to 100 once daily for cardiovascul

240 blind trial to investigate the efficacy of 3 aspirin regimens in optimizing platelet COX-1 inhibition

241 The incidence of aspirin resistance in aspirin-treated patients or platel

242 rin alone and TCT decreased the frequency of aspirin resistance in this group.

243 in and clopidogrel had a higher incidence of aspirin resistance than all patients treated with aspiri

244 ng aspirin and clopidogrel, the incidence of aspirin resistance was significantly decreased from 40%

245 Compared with aspirin, rivaroxaban increased TIMI major bleeding simil

246 esolvins and AT-lipoxins may explain some of aspirin's broad anticancer activity.

247 the risk of severe bleeding was higher with aspirin than placebo (absolute risk difference, 1.25% [9

248 ath within 30 days was lower with ticagrelor-aspirin than with aspirin alone, but the incidence of di

249 as significantly higher with rivaroxaban and aspirin than with aspirin alone.

250 1 year were significantly less frequent with aspirin than with aspirin plus clopidogrel administered

251 Discontinuation of aspirin therapy 1 to 3 months after PCI significantly re

252 studies evaluating the clinical efficacy of aspirin therapy after desensitization as well as a discu

253 ization, and recommendations for maintenance aspirin therapy following desensitization are reviewed.

254 The benefits of aspirin therapy for the secondary prevention of cardiova

255 s, aspirin desensitizations, and maintenance aspirin therapy in patients with AERD.

256 Guidelines recommended considering low-dose aspirin therapy only among adults 40 to 70 years of age

257 ernal care and possible chemoprevention (eg, aspirin therapy) to prevent preeclampsia, a disease that

258 ensitized to aspirin and maintained on daily aspirin therapy.

259 ch may help focus the use of rivaroxaban and aspirin therapy.

260 The overall NNT(5) with aspirin to prevent 1 cardiovascular disease event was 47

261 Meta-analyses of low-dose aspirin to prevent pre-eclampsia suggest that the incide

262 ls have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or tr

263 periority of rivaroxaban plus aspirin versus aspirin to reduce major cardiac and ischemic limb events

264 atabase of patients with N-ERD (n = 121) and aspirin-tolerant (n = 82) who underwent aspirin challeng

265 and lower respiratory tract disease than do aspirin-tolerant patients with CRSwNP.

266 ly different profile from global-COX-1-ko or aspirin-treated control mice, notably significantly high

267 The incidence of aspirin resistance in aspirin-treated patients or platelet inhibition in patie

268 We also show that aspirin-triggered 15-epi-lipoxin A(4) (15-epi-LXA(4)) an

269 le Haemophilus influenzae, using 17-HDHA and aspirin-triggered-resolvin D1 (AT-RvD1) as adjuvants.

270 rough 2015 and who did not have a history of aspirin use (50,275 patients).

271 ciated with increased risk of EOCRC, whereas aspirin use and being overweight or obese (relative to n

272 uggested a differential relationship between aspirin use and major bleeding based on aspirin use in t

273 ween aspirin use and major bleeding based on aspirin use in the 7 days prior to anticoagulation, such

274 Aspirin use prior to anticoagulation did not modify the

275 se results suggest that limiting clopidogrel-aspirin use to 21 days may maximize benefit and reduce r

276 associated with increased risk of EOCRC, and aspirin use to be significantly associated with decrease

277 In secondary analyses, low-dose aspirin use was assessed within exposure periods of 5 or

278 Aspirin use was not associated significantly with progre

279 y artery bypass graft surgery (CABG) despite aspirin use.

280 amily history of CRC, smoking, diabetes, and aspirin use.

281 s index (BMI), diabetes, smoking status, and aspirin use.

282 pylori (H. pylori) eradication and long-term aspirin use.

283 = 0.002) but not for those continuing prior aspirin use.

284 ical prosthesis, bridging therapies, role of aspirin, use of fibrinolytic therapy for prosthetic valv

285 year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9

286 e of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among nonusers of aspirin (differ

287 s more frequent with rivaroxaban 2.5 mg plus aspirin versus aspirin alone in those with GFR >=60 ml/m

288 demonstrated superiority of rivaroxaban plus aspirin versus aspirin to reduce major cardiac and ische

289 (HR) of 0.65 (95% CI 0.43-0.97; p=0.035) for aspirin versus placebo.

290 me enrolled into a randomised trial of daily aspirin versus placebo.

291 ents) over time with apixaban versus VKA and aspirin versus placebo.

292 fety of Apixaban vs Vitamin K Antagonist and Aspirin vs Aspirin Placebo in Patients With Atrial Fibri

293 ASPIRIN was a randomised, multicountry, double-masked, p

294 roxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incide

295 c viral hepatitis in Sweden, use of low-dose aspirin was associated with a significantly lower risk o

296 in in CCS have come from recent trials where aspirin was discontinued in specific clinical scenarios,

297 In women taking aspirin, we also observed significant reductions in peri

298 withdrawal of acetylsalicylic acid (ASA), or aspirin, while maintaining P2Y(12) inhibition.

299 Discontinuation of aspirin with continued P2Y(12) inhibitor monotherapy red

300 lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastroin